Rocket Pharmaceuticals Inc. (RCKT)
NASDAQ · Healthcare
Rocket Pharmaceuticals Inc. EBITDA 2016–2025
Rocket Pharmaceuticals Inc. annual/quarterly ebitda history and growth rate from 2018 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Rocket Pharmaceuticals Inc. ebitda for the quarter ending March 31, 2026 was -46.9 M, a 24.20% decrease year-over-year.
- Rocket Pharmaceuticals Inc. ebitda for the twelve months ending March 31, 2026 was -225.9 M, a 16.15% decrease year-over-year.
- Rocket Pharmaceuticals Inc. annual ebitda for 2025 was -222.8 M, a 16.22% decrease from 2024.
- Rocket Pharmaceuticals Inc. annual ebitda for 2024 was -266.0 M, a 4.41% increase from 2023.
- Rocket Pharmaceuticals Inc. annual ebitda for 2023 was -254.8 M, a 15.57% increase from 2022.
- Rocket Pharmaceuticals Inc. annual ebitda for 2022 was -220.4 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Rocket Pharmaceuticals Inc. EBITDA — FAQ
Rocket Pharmaceuticals Inc. (RCKT) ebitda over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see RCKT's ebitda history?
The chart and table above show Rocket Pharmaceuticals Inc.'s ebitda by year and by quarter, including the growth rate.